Smith & Nephew SNATS (SNN) Competitors

$29.84 -0.23 (-0.75%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$29.80 -0.03 (-0.10%)

As of 05/13/2026 04:59 PM Eastern

SNN vs. GEHC, PHG, ZBH, PEN, and SOLV

Should you buy Smith & Nephew SNATS stock or one of its competitors? MarketBeat compares Smith & Nephew SNATS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smith & Nephew SNATS include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Penumbra (PEN), and Solventum (SOLV). These companies are all part of the "medical equipment" industry.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GE HealthCare Technologies has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.37	$2.08B	$4.18	14.81
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

GE HealthCare Technologies presently has a consensus price target of $80.67, indicating a potential upside of 30.34%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 3.65%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe GE HealthCare Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

GE HealthCare Technologies has a net margin of 9.10% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.46% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Smith & Nephew SNATS	N/A	N/A	N/A

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for GE HealthCare Technologies and 2 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.91 beat Smith & Nephew SNATS's score of 0.23 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 13 of the 18 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Koninklijke Philips had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 5 mentions for Koninklijke Philips and 2 mentions for Smith & Nephew SNATS. Koninklijke Philips' average media sentiment score of 0.65 beat Smith & Nephew SNATS's score of 0.23 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Koninklijke Philips has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.22	$1.01B	$1.17	21.92
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 3.65%. Given Smith & Nephew SNATS's stronger consensus rating and higher probable upside, analysts clearly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

Koninklijke Philips has a net margin of 5.49% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Smith & Nephew SNATS	N/A	N/A	N/A

Koninklijke Philips pays an annual dividend of $0.82 per share and has a dividend yield of 3.2%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. Koninklijke Philips pays out 70.1% of its earnings in the form of a dividend.

Summary

Koninklijke Philips beats Smith & Nephew SNATS on 9 of the 16 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Smith & Nephew SNATS (NYSE:SNN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Smith & Nephew SNATS has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.2%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend.

Smith & Nephew SNATS currently has a consensus price target of $30.93, indicating a potential upside of 3.65%. Zimmer Biomet has a consensus price target of $102.80, indicating a potential upside of 24.35%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has a net margin of 9.05% compared to Smith & Nephew SNATS's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Zimmer Biomet	9.05%	13.24%	7.28%

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Zimmer Biomet had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 10 mentions for Zimmer Biomet and 2 mentions for Smith & Nephew SNATS. Zimmer Biomet's average media sentiment score of 0.85 beat Smith & Nephew SNATS's score of 0.23 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.47

Summary

Zimmer Biomet beats Smith & Nephew SNATS on 11 of the 16 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Penumbra?

Penumbra (NYSE:PEN) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Penumbra has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Smith & Nephew SNATS has higher revenue and earnings than Penumbra.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

Penumbra presently has a consensus price target of $361.33, indicating a potential upside of 12.05%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 3.65%. Given Penumbra's higher possible upside, research analysts plainly believe Penumbra is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

Penumbra has a net margin of 11.76% compared to Smith & Nephew SNATS's net margin of 0.00%. Penumbra's return on equity of 10.87% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Smith & Nephew SNATS	N/A	N/A	N/A

In the previous week, Penumbra had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 8 mentions for Penumbra and 2 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.23 beat Penumbra's score of 0.03 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Penumbra beats Smith & Nephew SNATS on 10 of the 15 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Solventum?

Solventum (NYSE:SOLV) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Solventum has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

Solventum presently has a consensus price target of $85.91, indicating a potential upside of 15.42%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 3.65%. Given Solventum's stronger consensus rating and higher possible upside, research analysts plainly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Smith & Nephew SNATS	N/A	N/A	N/A

In the previous week, Solventum had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Solventum and 2 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.30 beat Smith & Nephew SNATS's score of 0.23 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Solventum beats Smith & Nephew SNATS on 11 of the 15 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNN vs. The Competition

Export

Metric	Smith & Nephew SNATS	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$12.84B	$8.12B	$6.30B	$22.96B
Dividend Yield	3.11%	2.50%	2.79%	4.07%
P/E Ratio	N/A	18.19	21.21	28.29
Price / Sales	2.07	8.35	558.10	24.55
Price / Cash	8.77	16.76	42.94	25.11
Price / Book	2.40	3.75	9.70	4.73
Net Income	$625M	$223.05M	$3.55B	$1.07B
7 Day Performance	-0.90%	-2.05%	-0.56%	-1.11%
1 Month Performance	-13.17%	3.40%	1.17%	1.36%
1 Year Performance	6.52%	1.89%	41.19%	24.41%

Smith & Nephew SNATS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNN Smith & Nephew SNATS	2.5551 of 5 stars	$29.84 -0.7%	$30.93 +3.7%	+5.6%	$12.84B	$6.16B	N/A	16,988	Analyst Forecast
GEHC GE HealthCare Technologies	4.9477 of 5 stars	$60.82 -0.3%	$82.00 +34.8%	-16.2%	$27.64B	$20.63B	14.53	54,000	Insider Trade
PHG Koninklijke Philips	2.6858 of 5 stars	$26.58 +1.3%	N/A	+5.9%	$25.56B	$20.17B	25.05	65,340	Gap Down
ZBH Zimmer Biomet	4.5394 of 5 stars	$83.18 +0.6%	$102.43 +23.1%	-15.1%	$16.07B	$8.41B	21.56	17,000
PEN Penumbra	3.3802 of 5 stars	$324.36 -0.1%	$364.60 +12.4%	+9.1%	$12.75B	$1.40B	71.75	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SNN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew SNATS (SNN) Competitors

SNN vs. GEHC, PHG, ZBH, PEN, and SOLV

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Summary

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Summary

How does Smith & Nephew SNATS compare to Penumbra?

Summary

How does Smith & Nephew SNATS compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew SNATS (SNN) Competitors

SNN vs. GEHC, PHG, ZBH, PEN, and SOLV

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Do institutionals & insiders hold more shares of GEHC or SNN?

Which has more risk and volatility, GEHC or SNN?

Which has preferable valuation and earnings, GEHC or SNN?

Is GEHC or SNN a better dividend stock?

Do analysts rate GEHC or SNN?

Is GEHC or SNN more profitable?

Does the media refer more to GEHC or SNN?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Does the media refer more to PHG or SNN?

Which has more risk and volatility, PHG or SNN?

Which has preferable valuation and earnings, PHG or SNN?

Do institutionals & insiders hold more shares of PHG or SNN?

Do analysts rate PHG or SNN?

Is PHG or SNN more profitable?

Is PHG or SNN a better dividend stock?

Summary

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Which has more risk and volatility, SNN or ZBH?

Is SNN or ZBH a better dividend stock?

Do analysts prefer SNN or ZBH?

Is SNN or ZBH more profitable?

Do insiders and institutionals hold more shares of SNN or ZBH?

Does the media prefer SNN or ZBH?

Which has better earnings and valuation, SNN or ZBH?

Summary

How does Smith & Nephew SNATS compare to Penumbra?

Which has more volatility & risk, PEN or SNN?

Do insiders and institutionals have more ownership in PEN or SNN?

Which has stronger valuation and earnings, PEN or SNN?

Do analysts recommend PEN or SNN?

Is PEN or SNN more profitable?

Does the media refer more to PEN or SNN?

Summary

How does Smith & Nephew SNATS compare to Solventum?

Which has more volatility & risk, SOLV or SNN?

Do insiders and institutionals have more ownership in SOLV or SNN?

Which has stronger valuation and earnings, SOLV or SNN?

Do analysts recommend SOLV or SNN?

Is SOLV or SNN more profitable?

Does the media refer more to SOLV or SNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools